2nd Annual Highly Potent Active Pharmaceutical Ingredients Summit

November 2016



Crowne Plaza Berlin City Centre

Nürnberger Str. 65, 10787

About Summit

This premier B2B event will enable the participants to learn about the latest developments in the HPAPI industry. This summit will be focusing on the latest market development trends in the highly potent active pharmaceutical ingredients field, global standards, innovation challenges & expectations, sustainability, emerging markets, future trends & technological developments, and outsourcing.

Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Senior Managers, Principal Scientists, Principal Toxicologists, and Investigators Specialising in:

  • Research & Development
  • Risk Assessments
  • New Technologies
  • Environmental, Health & Safety
  • Industrial Hygiene
  • Product Quality
  • Innovations
  • Validation
  • Partnerships and Alliances
  • Sales Development
  • External Supply
  • Manufacturing
  • Laboratory Services
  • Process Development
  • Occupational Toxicology
  • New Products
  • Expertise
  • Regulatory
  • Business Development
  • Strategic Development
  • Formulation Development

From Industries Including:

  • Pharmaceutical
  • CRO
  • Non-profit organizations
  • Biotechnology
  • CMO
Key Practical Learning Points of the Summit

Strategies for the early development of linker-payloads for antibody-drug conjugates
Study and evaluation of the new containment life cycle
Discussion of human operating at HPAPIs facilities
Analysis of the value proposition for validating exposure controls associated with the handling of APIs
Observing technical and operational challenges in developing highly potent cytotoxic agents in a biotech environment
Manufacturing considerations in the development of highly potent compounds – scalability & robustness addressing risks for the upscale of highly potent compounds
Opportunities to meet and network with leading professionals during interactive sessions
Study of proactive integration of occupational toxicology assessments into the drug development planning process
Dr. Martin Butschies

Head of Laboratory Process Development Chemicals

Boehringer Ingelheim Pharma GmbH & Co. KG

Richard Denk

Head Containment Group

Skan AG

Dr. Ester Lovsin, MscTox, ERT

Head Health Hazard Assessment Center of Excellence (HHA CoE)

Novartis HSE & BCM

Dr. Graham Box

Senior Programme Manager

Patheon Inc.

Dr. Cynthia Wooge

Head of Process & Technology APIs, Excipients

Merck KGaA

Stefano Butti

Head of Sales Group




Sponsors and Partners